Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Quemliclustat and chemotherapy with or without zimberelimab in metastatic pancreatic adenocarcinoma: a randomized phase 1 trial.

  PMID 41912809 · PMC13099643 · Nature medicine · 2026 · 7 claims · 8 setups

  Full-text index only

  Quemliclustat combined with gemcitabine/nab-paclitaxel (G/nP) with or without zimberelimab has a safety profile consistent with G/nP alone across dose-escalation and dose-expansion phases

  mia hct-116 patients randomized rna-seq rt-pcr phase

• Characterizing gene perturbations in single cells via network divergence analysis.

  PMID 41965857 · PMC13249949 · Nature communications · 2026 · 8 claims · 8 setups

  Full-text index only

  scDNS quantifies gene-specific functional perturbations by measuring Jensen-Shannon divergence between condition-specific gene interaction network configurations

  ipsc-derived embryonic panc-1 triple scrna-seq single-nucleus

• NuRepress: Inferring Transcriptional Repressors from Phased Nucleosome Architecture.

  PMID 42074600 · PMC13115820 · Genes · 2026 · 7 claims · 8 setups

  Full-text index only

  NuRepress is a computational framework that predicts candidate transcriptional repressors by integrating repressive chromatin architecture, functional (accessibility) signatures, and transcriptional outcomes

  pancreatic patski well-phased chip-seq atac-seq rna-seq